Bayer hits back at Iberogast critics
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Bayer Consumer Health has instigated a pharmacy marketing campaign defending its Iberogast gastrointestinal brand following a series of attacks from a German Member of Parliament (MP).
You may also be interested in...
Bayer Stands By Iberogast As German Court Investigates Manslaughter Case
Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.